(Q44433132)

2 December 2017

title

D-cycloserine for the treatment of ataxia in spinocerebellar degeneration (English)

1 reference

2 December 2017

d-Cycloserine for the treatment of ataxia in spinocerebellar degeneration (English)

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(03)00009-1

31 December 2023

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(03)00009-1

31 December 2023

author name string

Masafumi Ogawa

1

1 reference

2 December 2017

Hiroshi Shigeto

2

1 reference

2 December 2017

Toshiyuki Yamamoto

3

1 reference

2 December 2017

Yasushi Oya

4

1 reference

2 December 2017

Keiji Wada

5

1 reference

2 December 2017

Toru Nishikawa

6

1 reference

2 December 2017

Mitsuru Kawai

7

1 reference

2 December 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12736088

31 December 2023

publication date

1 June 2003

1 reference

2 December 2017

15 June 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12736088

full work available at URL

31 December 2023

number of pages

4

1 reference

based on heuristic

inferred from page(s)

https://api.elsevier.com/content/article/PII:S0022510X03000091?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(03)00009-1

https://api.elsevier.com/content/article/PII:S0022510X03000091?httpAccept=text/plain

31 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(03)00009-1

Journal of the Neurological Sciences

31 December 2023

published in

1 reference

2 December 2017

volume

210

1 reference

2 December 2017

issue

1-2

1 reference

2 December 2017

page(s)

53-56

1 reference

Ataxia and hereditary disorders

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900009-1

Glutamate dehydrogenase deficiency in spinocerebellar degenerations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900009-1

Brain amino acid reductions in one family with chromosome 6p?linked dominantly inherited olivopontocerebellar atrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900009-1

Neurotransmitter amino acids in dominantly inherited cerebellar disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900009-1

The behavioral pharmacology of NMDA receptor antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900009-1

Motor discoordination results from combined gene disruption of the NMDA receptor NR2A and NR2C subunits, but not from single disruption of the NR2A or NR2C subunit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900009-1

3-Acetylpyridine: a tool to inhibit the tremor and the increase of cGMP content in cerebellar cortex elicited by harmaline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900009-1

Concentrations of glutamic acid in cerebellar cortex and deep nuclei of normal mice and weaver, staggerer and nervous mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900009-1

D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900009-1

D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900009-1

The stereo-specific effect of D-serine ethylester and the D-cycloserine in ataxic mutant mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900009-1

Consensus statement on the diagnosis of multiple system atrophy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900009-1

International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900009-1

Hippocampus-dependent learning facilitated by a monoclonal antibody or D-cycloserine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900009-1

The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900009-1

Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900009-1

Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900009-1

Tolerability of oral dextromethorphan in patients with a history of brain ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900009-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Glutamate dehydrogenase deficiency in three patients with spinocerebellar ataxia: a new enzymatic defect?

3

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(03)00009-1

Phencyclidine: an overview

31 December 2023

7

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(03)00009-1

31 December 2023

Identifiers

1 reference

2 December 2017

1 reference